EXHIBIT 10.1


 


EXECUTION COPY


ASSIGNMENT AGREEMENT


 


This Assignment Agreement
(“Agreement”) is between the University of Utah Research Foundation, having a place of business at 615 Arapeen Dr.,
Suite 310, Salt Lake City, UT 84108 (hereinafter referred to as “Foundation”), and BioRestorative Therapies, Inc.,
a Nevada corporation having its principal place of business at 555 Heritage Drive, Jupiter, FL 33458 (hereinafter referred to as
“BRT”).


 


1. Recitals


 


1.1.        Whereas,
Foundation owns all right, title and interest in and to the Patents (as defined below), which Patents were created at The University
of Utah (“University”).


 


1.2.        Whereas,
BRT desires to acquire and Foundation is willing to assign to BRT all of Foundation’s right, title, and interest in and to
the Patents and any inventions disclosed and claimed therein.


 


1.3.        Whereas,
Foundation has determined that such assignment, use, development and commercialization of the Patents is in the public’s
best interest and is consistent with Foundation’s educational and research missions and goals.


 


1.4          Whereas,
Foundation has provided to BRT copies of the provisional application with respect to the Patents and the assignment from the inventors
thereof to Foundation, in each case as filed with the United States Patent and Trademark Office .


 


NOW, THEREFORE, in consideration of the
mutual covenants and premises herein contained, the parties agree as follows:


 


2. Definitions


 


		2.1	“Affiliate” means any Entity that controls, is controlled by, or is under common
control with BRT, directly or indirectly. For purposes of this definition, “control” and its various inflected forms
means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such
Entity, whether through ownership of voting securities, by contract or otherwise.



 


		2.2	“Effective Date” means June 15, 2012.



 


		2.3	“Entity” means any individual, corporation, partnership, limited liability company,
joint venture, association, joint-stock company, trust, unincorporated organization or government.



 


University
of Utah


Technology Commercialization Office




 



    	Page 1 of 12



    	 



    

 


		2.4	“Know-How” means all information, know-how, show-how, ideas, data, inventions,
designs, specifications, processes, techniques, formulae, sketches, drawings, models, databases, research, experimental work, development,
software programs and applications, software source documents, studies, works of authorship, trade secrets, technology and other
intellectual property rights.



 


		2.5	“Licensee” means any party that enters into an agreement or arrangement with
BRT, or receives a license grant from BRT under the Patents, to manufacture, have manufactured, offer for sale, sell, lease, distribute,
market and/or import the Products (a “License Agreement”). “Licensee” also means any corporate or business
entity established by BRT for the commercialization or Sale of Products.



 


		2.6	“Patent Revenue” means any monies, royalties, payments, cash equivalent (including
non-cash consideration), or other consideration received by BRT or any of its Affiliates from third parties from the use, lease,
other commercialization, licensing, infringement, litigation (after deduction of all reasonable costs of litigation directly related
to achieve recovery) or Sale of the Patents. In no event will “Patent Revenue” include any of the following: (a) cash,
quantity and other trade discounts, credits or allowances; (b) credits or allowances granted upon returns, rejections or recalls;
(c) amounts payable resulting from governmental (or any agency thereof) mandated rebate programs; (d) chargebacks and other amounts
paid on the sale or dispensing of Products; (e) taxes, tariffs and duties; (f) transportation, freight, postage, importation, insurance
and other handling expenses; (g) delayed ship order credits; (h) discounts pursuant to indigent patient programs and patient discount
programs and coupon discounts; (i) amounts received from Foundation or the University or any Affiliate thereof; (j) amounts received
as grants from any governmental body, quasi-governmental body or foundation; or (k) amounts received from third parties in connection
with clinical trials.



 


		2.7	“Patents” means and includes all of the following Foundation intellectual property:
the United States patents and/or patent applications listed in Exhibit “B”; United States patents issued from the applications
listed in Exhibit “B” and from divisionals and continuations (other than continuations-in-part) of these applications
and any reissues of such United States patents; claims of continuation-in-part applications and patents directed to subject matter
specifically described in the applications listed in Exhibit “B”; and claims of all foreign applications and patents
which are directed to subject matter specifically described in the United States patents and/or patent applications listed in Exhibit
“B”.



 


		2.8	“Products” means any product or products, apparatus, kit or component part thereof,
method, procedure, process, or any other subject matter the manufacture design, creation, use, importation, distribution, or sale
of which is covered by any claim or claims included within the Patents. Products will also include any service rendered through
the use of a product, process, method, or machine covered by any claim of the Patents.



 


		2.9	“Revenue Report” means the report due from BRT to Foundation as set forth in
Section 5.1 below and as in the form set forth in Exhibit “C”.



 


		2.10	“Sublicensee” means any party that enters into an agreement or arrangement with
a Licensee, or receives a license grant from a Licensee or a Sublicensee under the Patents, to manufacture, have manufactured,
offer for sale, sell, lease, distribute, market and/or import the Products (a “Sublicense Agreement”).



 


University
of Utah


Technology Commercialization Office







 



    	Page 2 of 12



    	 



    

 


		2.11	“Sale, Sell or Sold” means any bona fide transaction for which consideration
(cash, cash equivalents and non-cash) is received or expected for the sale, use, lease, transfer, or other disposition of the Patents.
A Sale will be deemed completed at the time BRT receives payment.



 


3. Assignment


 


		3.1	Concurrent with the execution of this Agreement, Foundation shall execute and deliver to BRT the
Assignment attached hereto as Exhibit “A”, which transfers, grants, conveys, assigns, and relinquishes exclusively
to BRT all of Foundation’s right, title, and interest in and to the Patents and the inventions claimed therein in perpetuity.
Foundation further agrees to perform any reasonable act deemed necessary or helpful to carry out the intent of this Agreement.



 


		3.2	In furtherance of this Agreement, Foundation hereby acknowledges that, from the Effective Date
forward, BRT has succeeded to all of Foundation’s right, title, and standing to receive all rights and benefits pertaining
to the Patents, to institute and to prosecute all suits and proceedings and to take all actions that BRT, in its sole discretion,
may deem necessary or proper to collect, assert, or enforce any claim, right, or title of any kind under any and all of the Patents,
whether arising before or after the Effective Date, to defend any and all such actions, suits, or proceedings relating to such
transferred and assigned right, title, interest, and benefits, and to do all other such acts and things in relation thereto as
BRT, in its sole discretion, deems advisable.



 


4.
Payments and Fees


 


In consideration for the assignment of
the Patents by Foundation to BRT, BRT agrees that:


 


		4.1	Payments



 


		a.	BRT will pay Foundation a non-refundable assignment fee of fifteen thousand dollars ($15,000) (the
“Assignment Fee”) at the time of the execution of this Agreement. The Assignment Fee shall be deemed earned and immediately
payable upon execution of this Agreement. Failure to pay the Assignment Fee on or before thirty (30) days following execution of
this Agreement by both parties shall terminate this Agreement.



 


		b.	In addition, in consideration of the accuracy of the representations and warranties made in this
Agreement, BRT will pay Foundation a royalty equal to five percent (5%) of Patent Revenue for a period of twenty (20) years from
the Effective Date (the “Royalty Term”). Payments will be made simultaneously with the delivery of the Revenue Reports
required under Section 5.1.



 


University of Utah


Technology Commercialization Office







 



    	Page 3 of 12



    	 



    

 


		4.2	Future Patent Expenses



BRT understands that it will,
at its discretion, be responsible for all Patent costs incurred from the Effective Date.


 


		4.3	Reference



Each payment will reference U-5283.


 


5. Reports


 


		5.1	Revenue Reports



Upon the execution of a License
Agreement, Sublicense Agreement or first Sale, BRT will, within thirty (30) days after the calendar year in which Patent Revenue
first occurs, and within thirty (30) days of each July 1 and January 1 thereafter, deliver to Foundation a true and accurate written
Revenue Report, giving the particulars of the business conducted with the Patents during the preceding six (6) calendar months
as are pertinent to calculating payments hereunder. The Revenue Report will be in the form set forth in Exhibit “C”
(Form of Revenue Report). BRT will deliver Revenue Reports to Foundation during the Royalty Term.


 


Reports will be sent to:


 


University of Utah Research Foundation


Technology Commercialization Office


Re: U-5283.


615 Arapeen Dr., Suite 310


Salt Lake City, UT 84108


 


6. Payment, Records, and Audits


 


		6.1	Payments



All dollar amounts referred
to in this Agreement are expressed in United States dollars without deduction of exchange, collection, wiring fees, bank fees,
taxes, assessments, fees, or any other charges. Each payment will reference U-5283. All payments to Foundation will be made in
United States dollars by wire transfer or check payable to the University of Utah Research Foundation and sent to:


 


Technology Commercialization
Office


Attn: Accounts Receivable


The University of Utah


615 Arapeen Dr. #310


Salt Lake City, UT 84108


 


		6.2	Late Payments



In the event that payments
or other fees are not received by Foundation when due hereunder, and such failure continues unremedied for a period of fifteen
(15) days following receipt of written notice thereof from Foundation, BRT shall pay to Foundation interest charges at the rate
of twelve percent (12%) per annum on the total unpaid payments or fees due for the reporting period.


 


University of Utah


Technology Commercialization Office




 



    	Page 4 of 12



    	 



    

 


		6.3	Records



BRT will maintain, and cause its
Licensees and Affiliates to maintain, complete, true and accurate books and records that may be necessary for the purpose of showing
the amounts payable to Foundation hereunder. The records supporting each Revenue Report will be maintained for three (3) years
after the submission of each report under Section 5.1.


 


		6.4	Auditing



Said books and records, and the
supporting data, shall be open at all reasonable times for five (5) years following the end of the calendar year to which they
pertain, to inspection by Foundation or its agents, upon reasonable prior notice to BRT, for the purpose of verifying BRT’s
Revenue Reports and payments or compliance in other respects with this Agreement. Such access will be available to Foundation during
normal business hours upon not less than ten (10) days written notice to BRT, not more than once each calendar year during the
Royalty Term, and once during the year immediately following the expiration of the Royalty Term. The results of such inspection
shall be made available to BRT promptly. In the event such inspection demonstrates a greater than ten percent (10%) discrepancy
in reporting to Foundation’s detriment, BRT agrees to pay the full reasonable cost of such inspection. Any information or
data obtained by Foundation or its agents shall be kept strictly confidential and shall not be used for any purpose other than
to determine the amount of royalties payable to Foundation hereunder.


 


7. Infringement and Litigation


 


		7.1	Notification



 


		a.	BRT is responsible for notifying Foundation in the Revenue Report of any litigation concerning,
or infringement of, Patents that may come to its attention.



 


		b.	Foundation will notify BRT of any litigation concerning, or infringement of, Patents that may come
to its attention.



 


8. Warranty and Indemnification


 


		8.1	Foundation represents and warrants that (a) it has the right to enter into this Agreement and to
assign all of its right, title and interest in and to the Patents to BRT, (b) it owns all right, title and interest in and to the
Patents free and clear of any and all liens, security interests, claims and other encumbrances and (c) neither Foundation nor University
has received any notice, written or oral, and neither Foundation nor University otherwise has any knowledge that, the Patents infringe,
or that any Entity claims that the Patents infringe, the intellectual property rights of any Entity; provided, however, that, with
respect to (c) above, no representation or warranty is made with respect to any University employee other than Dr. Amit Patel and
persons working under his direct or indirect supervision.



 


University of Utah


Technology Commercialization Office




 



    	Page 5 of 12



    	 



    

 


		8.2	EXCEPT AS EXPRESSLY PROVIDED IN SECTION 8.1, THE PARTIES ACKNOWLEDGE AND AGREE THAT FOUNDATION
HAS MADE NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY OR FITNESS
FOR A PARTICULAR PURPOSE. IN NO EVENT SHALL FOUNDATION BE HELD RESPONSIBLE FOR ANY SPECIAL, INDIRECT OR CONSEQUENTIAL DAMAGES ARISING
OUT OF THE USE OF PATENTS, EVEN IF FOUNDATION IS ADVISED IN ADVANCE OF THE POSSIBILITY OF SUCH DAMAGES.



 


		8.3	Nothing in this Agreement shall be construed as:
	 	 	 



		a.	a warranty or representation by Foundation as to the validity or scope of any Patents;



 


		b.	a warranty or representation by Foundation that anything made, used, sold or otherwise disposed
of pursuant to any rights granted under this Agreement is or will be free from infringement of intellectual property rights of
third parties; 



 


		c.	an obligation by Foundation to bring or prosecute actions or suits against third parties for patent
infringement;
	 	 	 



		d.	conferring by implication, estoppel or otherwise any license or rights under any patents of Foundation
other than the Patents.



 


		8.4	BRT shall indemnify, hold harmless and defend Foundation, the University and their respective officers,
employees and agents, against any and all claims, suits, losses, damages, costs, liabilities, fees and expenses (including reasonable
fees of attorneys) resulting from or arising out of : (a) exercise of the rights granted to BRT under this Agreement; (b) any act,
error, or omission of BRT, its agents, employees, Affiliates, or Sublicensees; or (c) use, commercialization, or enforcement of
the Patents. Foundation shall give BRT timely notice of any claim or suit instituted of which Foundation has knowledge, and Foundation
shall have the right at its own expense to participate in the defense of the same.



 


		8.5	Foundation is a government entity and is subject to the Utah Governmental Immunity Act, Section
63-30d-101 et seq., Utah Code Ann. (1997 and Supp. 2005), as amended (the “Act”). Subject to the Act, Foundation shall
indemnify, defend and hold harmless BRT, its directors, officers, agents and employees against any and all claims, suits, losses,
damages, costs, liabilities, fees and expenses (including reasonable fees of attorneys) resulting from negligent acts by Foundationpursuant
to this Agreement. Nothing in this Agreement shall be construed as a waiver of any rights or defenses applicable to Foundation
under the Act, including without limitation, the provisions of Section 63-30d-604 regarding limitation of judgments.



 


		8.6	Notwithstanding any provision in this Agreement to the contrary, Foundation’s aggregate liability
under this Agreement shall not exceed the aggregate amounts received by Foundation from BRT, its Affiliates, Licensees and Sublicensees
pursuant to Section 4 (Payments and Fees) hereunder from and after the Effective Date.



 


University
of Utah


Technology Commercialization Office




 



    	Page 6 of 12



    	 



    

 


9. Publicity


 


		9.1	Publicity. Neither party shall have the right to make any public announcements or other
disclosures with respect to this Agreement, nor disclose the terms of this Agreement, without the prior written consent of the
other party, except as follows:



 


		a.	Upon BRT’s request, the parties shall exercise good faith efforts to reach agreement on the
text of a press release regarding this Agreement.



 


		b.	Each party may disclose the terms of this Agreement to the extent such disclosure is required by
law (including without limitation by rules or regulations of the Securities and Exchange Commission, any securities exchange or
NASDAQ) or to defend or prosecute litigation or arbitration; provided, that, prior to such disclosure, to the extent permitted
by law or such rules or regulations, the disclosing party promptly notifies the other party of such requirement and the disclosing
party furnishes only those terms of this Agreement that the disclosing party is legally required to furnish.



 


		c.	BRT may disclose this Agreement to (i) BRT’s then-current and potential Licensees and Sublicensees,
and (ii) BRT’s then-current and potential directors, investors, lenders and acquirers; provided, that such Entities are bound
to maintain the confidentiality of this Agreement to the same extent as if they were parties hereto



 


10. Miscellaneous


 


		10.1	Foundation and University shall retain a royalty free, nonexclusive license to practice the Patents
solely for academic research and educational non commercial uses, which shall include the right to publish the general scientific
findings from research conducted in whole or in part at the University related to the Patents and include such findings in grant
applications.



 


		10.2	This Agreement shall inure to the benefit of, and be binding upon, the parties hereto together
with their respective legal representatives, successors, and assigns.



 


		10.3	This Agreement merges and supersedes all prior and contemporaneous agreements, assurances, representations,
and communications between or among the parties hereto concerning the matters set forth herein.



 


		10.4	Subject to the provisions of the Research Agreement of even date by and between BRT and University,
it is understood that any inventions, developments and improvements developed in the future shall belong to University according
to policy, where applicable.



 


[Remainder of page intentionally left blank.
Signature page follows.]


 


University of Utah


Technology Commercialization Office




 



    	Page 7 of 12



    	 



    

 


IN WITNESS WHEREOF,
the parties hereto have caused their duly authorized representatives to execute this Agreement.


 


	BioRestorative Therapies, Inc.	 	University of Utah Research Foundation	 
	 	 	 	 
	By:	/s/ Mark Weinreb	 	By:	/s/ Thomas N. Parks	 
	 	(Signature)	 		(Signature) 	 
	 	 	 	 	 	 
	Name:	Mark Weinreb	 	Name:	Thomas N. Parks	 
	 	 	 	 	 	 
	Title:	Chief Executive Officer	 	Title:	President	 
	 	 	 	 	 	 
	Date:	June 8, 2012	 	Date:	June 18, 2012	 


 


University of Utah


Technology Commercialization Office




 






    	Page 8 of 12



    	 



    
 


EXHIBIT A


 


ASSIGNMENT


 


Whereas, University of Utah Research Foundation,
a corporation of the State of Utah, having a place of business at 615 Arapeen Dr., Suite 310, Salt Lake City, UT 84108 is the owner
of the entire right, title and interest in and to application for United States Letters Patent entitled Methods of Derivation &
Isolation of Human Brown Fat Cell Lines, filed in the United States Patent and Trademark Office as Serial No. 61/632,122 on January
18, 2012 and to application for United States Letters Patent entitled Methods of Derivation & Isolation of Human Brown Fat
Cell Lines, filed in the United States Patent and Trademark Office as Serial No. 61/632,516 on January 25, 2012 which applications
are incorporated herein by this reference; and the invention therein described; and


 


Whereas, BioRestorative Therapies, Inc.,
a corporation of the State of Nevada, having a place of business at 555 Heritage Drive, Suite 130, Jupiter, Florida 33458 (“BRT”)
is desirous of acquiring the entire right, title and interest in and to the said inventions within the United States of America
and its territorial possessions and within the countries foreign to the United States and any United States or foreign Letters
Patent that may be granted therefor; and in and to said applications;


 


Now, Therefore, in consideration of the
sum of One Dollar ($1.00) paid by BRT to the University of Utah Research Foundation and other good and valuable consideration,
the receipt of which is hereby acknowledged, the University of Utah Research Foundation has sold, assigned and transferred and
by these presents does hereby sell, assign and transfer unto the said BRT the entire right, title and interest in and to the said
inventions within the United States of America and its territorial possessions and within all countries foreign to the United States
and in and to any United States or foreign Letters Patent that may be granted therefor and in and to the said applications and
in and to any and all divisions, reissues, continuations, continuations in part, and extensions thereof and in and to any Letters
Patent that may be granted thereon, all said rights to be held and enjoyed by BRT for its own use and enjoyment, and the use and
enjoyment of its successors and assigns, to the full end of the term or terms for which said Letters Patent may be granted as fully
and entirely as the same would have been held and enjoyed by the University of Utah Research Foundation if this assignment, transfer
and sale had not been made.


 


The University of Utah Research Foundation
hereby authorizes and requests the United States Commissioner of Patents and Trademarks and all authorized officials of foreign
patent offices to issue the said Letters Patent, when granted, to said BRT as the Inventor(s) of its entire right, title and interest
in and to the same, for the sole use and enjoyment of said BRT, its successors and assigns.


 


University of Utah


Technology Commercialization Office




 



    	Page 9 of 12



    	 



    

 


In Testimony Whereof, the University
of Utah Research Foundation has caused the hand of its proper representative to be subscribed hereto this ________day of
_____________________ , 2012.


 


	 	UNIVERSITY OF UTAH RESEARCH FOUNDATION
	 	 
	 	By	 


 


STATE OF
UTAH                                         )


: ss.


COUNTY OF
SALT LAKE                          )


 


On
_____________________________________________________ , 2012, before me personally appeared ________________.,
________________ of said University of Utah Research Foundation known to me to be the person described and who signed the
foregoing Assignment in my presence and acknowledged under oath before me that he has read the same and knows the contents
thereof and that the same is true of his own knowledge excepting as to matters therein alleged upon information and belief
and as to those matters he believes them to be true, and that he executed the same as his free act and deed and for the
purposes set forth therein.


 


	 	NOTARY PUBLIC
	 	Residing at


 


	My Commission expires:	 
	 	 


 


University of Utah


Technology Commercialization Office







 



    	Page 10 of 12



    	 



    

 


EXHIBIT
B: PATENTS


 





	U#	 	Matter	 	
        United States

        Serial No. or

        Foreign

        Application

        No.
	 	Title	 	Inventor(s)
	U-5283	 	 	 	61/632,122	 	Methods of Derivation & Isolation of Human Brown Fat Cell Lines	 	
        Dr. Amit N. Patel

        Dr. David A. Bull

	 	 	 	 	 	 	 	 	 
	U-5283	 	 	 	61/632,516	 	Methods of Derivation & Isolation of Human Brown Fat Cell Lines	 	
        Dr. Amit N. Patel

         





 





University
of Utah


Technology Commercialization Office




 



    	Page 11 of 12



    	 



    

 


EXHIBIT
C: FORM OF REVENUE REPORT


 


	Name:	 	 


 


	Period Covered:	From:	 	/	/	through:	 	/	/	 


 


	Prepared by:	 	 	Date: 	 


(BRT) 


	Approved by:	 	 	Date: 	 


(BRT)


If license covers several major product
lines, please prepare a separate report for each line. Then combine all product lines into a summary report.


 


	Report Type:	£	Single Product or Process Line Report: 	 
	 	 	 	(product name)
	 	£	Multiproduct Summary Report, page 1 of ________ pages
	Other Compensation:	£	Annual payments, other fees & compensation: _______________________
	 	 	Amount due: _____________
	 	£	No Compensation or Royalty Due this Period
	 	 	Reason why:	 
	 	 	 	 	 


Litigation                or
                     Infringement:
                                Please
                         provide
                            details


                                                                                                     


 





 



 





 



 


	Country	Quantity

Produced	Quantity

Sold	
        Net 

        Sales ($)
	
        Royalty

        Rate
	
        Conversion

Rate

        (if applies)
	Royalty

Due This

Period
	USA	 	 	 	 	 	 
	Canada	 	 	 	 	 	 
	Japan	 	 	 	 	 	 
	Other:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	TOTAL:	 	 	 	 	 	 


 


University of Utah


Technology Commercialization Office




 



    	Page 12 of 12